SCHEMBL29042384

SCHEMBL29042384

CC1(C)OC(c2ccc3[nH]ccc3c2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 4/20 0.42
▸ NR4A2 P43354 2/20 0.42
▸ CYP2A6 P11509 2/20 0.42
▸ F7 P08709 1/20 0.42
▸ LTA4H P09960 1/20 0.42
▸ F3 P13726 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ RAD51 Q06609 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ SLC6A2 P23975 2/20 0.40
▸ SLC6A4 P31645 2/20 0.40
▸ SLC6A3 Q01959 2/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ IMPDH2 P12268 1/20 0.39
▸ IMPDH1 P20839 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29042371 0.87 MEN1 (0.42) AHRCYP2A6SLC6A2SLC6A4SLC6A3
SCHEMBL30286426 0.74 NOS1 (0.45) GAASLC6A2SLC6A4SLC6A3MAPT
SCHEMBL17863581 0.71 MAPK1 (0.37) NPC1CYP2C19RAB9A
SCHEMBL18000304 0.69 AHR (0.48) AHRNR4A2CYP2A6F7LTA4H
SCHEMBL31692600 0.69 MAPT (0.39) AHRNR4A2CYP2A6F7LTA4H
SCHEMBL31339237 0.69 MAPT (0.39) AHRNR4A2CYP2A6F7LTA4H
SCHEMBL28915933 0.68 AHR (0.47) AHRMAPTRAB9A
SCHEMBL31263028 0.67 SLC6A2 (0.36) AHRNR4A2CYP2A6F7LTA4H
SCHEMBL9946120 0.67 HTR2A (0.37) —
SCHEMBL8995188 0.67 AHR (0.46) AHRNR4A2CYP2A6F7LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115279741-A 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders 医肯纳肿瘤学公司 2022-11-01 — — CN disclosed
Send feedback